Cellana Inc. develops and produces algae-based bioproducts. It focuses on producing marine microalgae, which is used as a feedstock for various products, including ReNew line of omega-3 EPA and DHA nutritional oils, food/animal feed, and biofuel feedstock. The company also produces nutraceuticals, such as astaxanthan and beta carotene. In addition, it evaluates various commercial algae facility locations in the United States, the Middle East North Africa, and Southeast Asia. The company serves human nutrition (Omega-3), animal nutrition, and biofuel markets. Cellana Inc. was formerly known as HR BioPetroleum, Inc. and changed its name to Cellana Inc. on April 25, 2011. The company was founde...
10685 Roselle Street
San Diego, CA 92121
Founded in 2004
Cellana Appoints David Anton as Chief Operating Officer and Board Director
Mar 11 15
Cellana, Inc. announced that David Anton, Ph.D., was appointed as chief operating officer and elected to the board of directors of the company. In the COO position, Dr. Anton will lead the transition of Cellana's paradigm-shifting ALDUO algae cultivation technology platform into a commercial reality. He brings over 30 years of technology and product development experience to the company, including prior leadership roles at DuPont, Codexis and Joule. Before joining Cellana, he held C-level roles at Joule Unlimited, Inc., and Codexis Inc.
Cellana, Inc. Signs Letter of Intent with Galil Algae for the Commercialization of High-Value Algae Biomass for Aquaculture and Other High-Value Applications
Jun 23 14
Cellana, Inc. announced that it has entered into a letter of intent with Galil Algae Cooperative Agriculture Society Limited with the objective of partnering for the production of high-value algae products for aquaculture applications. Currently, Cellana produces industrial-scale quantities of ReNew(TM) Algae -- high-value algae biomass rich in Omega-3 nutritional oils, proteins, fuel-grade oils, cosmetic-grade oils, acids, and polysaccharides, as well as other valuable micronutrients -- at its Kona Demonstration Facility in Hawaii. At its facility in northern Israel, Galil Algae currently produces a variety of whole-algae products that are rich in Omega-3s for aquaculture applications. The main goal of the program contemplated by the letter of intent is to identify, cultivate, develop and scale up algae strains with immediate commercial value, emphasizing the high-value components for existing aquaculture, mariculture, nutraceuticals, pharmaceutical and/or cosmetic applications. The starting points for the commercial venture are to include the existing high-Omega-3 algae strains of Cellana and Galil Algae, as well as (i) potential new and improved strains identified through non-GMO strain optimization techniques such as selective breeding and/or (ii) additional naturally occurring strains identified through bioprospecting. In addition, the letter of intent contemplates Cellana and Galil Algae exploring the establishment of a new algae research and development center in northern Israel. This new R&D center, together with the R&D activities to be undertaken at Cellana's facility in Hawaii, would be a focal point for the development and testing of new or optimized strains of high-value algae biomass.